3 Global Pharmaceutical Company, Power Conductors Maker and Gaskets and Forgings Maker Stocks With a Strong Future Roadmap: Lupin, Dhoot Transmission and Talbros Automotive Components
- November 5, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Lupin, Dhoot Transmission and Talbros Automotive Components: ROE of 14.0% to 23.8% and FY22 to FY26 revenue CAGR of 10.9% to 31.0%. Prices as of 4 Nov 2026.
Quick Answer
The three pharma major, power conductor and gasket stocks to watch are Lupin, Dhoot Transmission and Talbros Automotive Components. Their return on equity ranges from 14.0% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.9% to 31.0%. Lupin has the highest return on equity at 23.8%, while Dhoot Transmission has the fastest revenue growth at 31.0% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Pharma major, power conductor and gasket stocks let investors follow companies that serve a growing part of the Indian economy. Lupin, Dhoot Transmission and Talbros Automotive Components cover a global pharmaceutical company, a power conductors maker and a gaskets maker.
This list covers three pharma major, power conductor and gasket stocks with complete current figures: Lupin, Dhoot Transmission and Talbros Automotive Components. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Major, Power Conductor and Gasket Stocks?
Pharma major, power conductor and gasket stocks are listed companies that sell branded and generic medicines in India and overseas, make conductors, cables and wiring harnesses for power transmission, and produce gaskets, forgings and heat shields for vehicles. Their earnings depend on prescriptions, grid projects and vehicle output.
Pharma Major, Power Conductor and Gasket Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lupin | 2,008.6 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
| Dhoot Transmission | 1,637.2 | 30,067 | 75.8 | 40.7 | 16.3 | 0.38 |
| Talbros Automotive Components | 369.25 | 2,171 | 19.4 | 36.9 | 14.0 | 0.11 |
On valuation, Lupin and Talbros Automotive Components trade at a P/E below the industry P/E, while Dhoot Transmission trades above it, which reflects the growth the market already expects. Readers comparing pharma major, power conductor and gasket stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma major, power conductor and gasket stocks can use the coming numbers to test whether growth is holding.
Why Do Pharma Major, Power Conductor and Gasket Stocks Have a Strong Roadmap in India?
Pharma major, power conductor and gasket stocks have a strong roadmap in India because steady demand for quality medicines, large grid investment and rising vehicle output keep widening the market for these companies.
- Pharma. Branded and generic medicines reach more patients.
- Power conductors. Grid upgrades need new lines.
- Gaskets. Every engine needs sealing parts.
Why Lupin Features Among These Pharma Major, Power Conductor and Gasket Stocks
Among the pharma major, power conductor and gasket stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Why Dhoot Transmission Features Among These Pharma Major, Power Conductor and Gasket Stocks
Among the drug, electrical and auto part shares on this list, Dhoot Transmission makes power conductors, cables and wiring harnesses used in power transmission, distribution and vehicles.
Revenue rose from Rs 1,551 crore in FY22 to Rs 4,564 crore in FY26, a compound annual growth rate of 31.0%. Net profit grew from Rs 164 crore in FY23 to Rs 397 crore in FY26, which works out to a compound annual growth rate of 34.3%.
In the June 2026 quarter, revenue grew 49.9% year on year to Rs 1,460 crore, while net profit rose 37.8% to Rs 133 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 30,067 crore. The stock trades at a P/E of 75.8, above the industry P/E of 40.7.
Roadmap: The company is expanding capacity in power conductors and cables to serve utilities and grid projects, while its wiring harness business supplies vehicle makers. Rising spending on power transmission supports demand for its products.
What to watch: Follow capacity expansion, order inflows from utilities and metal price movements.
Why Talbros Automotive Components Features Among These Pharma Major, Power Conductor and Gasket Stocks
Among the three companies on this list, Talbros Automotive Components makes gaskets, forgings, heat shields and anti-vibration products for automakers and the aftermarket, and is part of the Talbros group.
In the June 2026 quarter, revenue grew 15.0% year on year to Rs 242 crore, while net profit rose 35.2% to Rs 30.0 crore. Revenue rose from Rs 588 crore in FY22 to Rs 889 crore in FY26, a compound annual growth rate of 10.9%.
Net profit grew from Rs 44.9 crore in FY22 to Rs 104 crore in FY26, which works out to a compound annual growth rate of 23.4%. The company has a return on equity of 14.0%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,171 crore. The stock trades at a P/E of 19.4, below the industry P/E of 36.9.
Roadmap: Its roadmap includes capacity in forgings, entry into products for electric vehicles and a growing export book. The aftermarket business offers steady demand through the vehicle’s life, which provides a base for earnings.
What to watch: Monitor demand from major vehicle customers and raw material price trends.
Lupin vs Dhoot Transmission vs Talbros Automotive Components on Key Financials
The table below sets the three pharma major, power conductor and gasket stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
| Dhoot Transmission | 1,551 | 4,564 | 31.0% | 397 | 8.7% |
| Talbros Automotive Components | 588 | 889 | 10.9% | 104 | 11.7% |
Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Dhoot Transmission shows the fastest revenue growth with a 31.0% compound annual rate. A useful habit with pharma major, power conductor and gasket stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several branded generics, cable and forging stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Lupin | 6,347 | 8,407 | 32.5% |
| Dhoot Transmission | 974 | 1,460 | 49.9% |
| Talbros Automotive Components | 211 | 242 | 15.0% |
Key Risks to Check Before Investing in Pharma Major, Power Conductor and Gasket Stocks
Every theme carries risks that deserve a check before any decision. For these pharma major, power conductor and gasket stocks, the main points are: Long-term drug, electrical and auto part shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Order timing. Project awards can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma major, power conductor and gasket stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma Major, Power Conductor and Gasket Stocks
Pharma major, power conductor and gasket stocks reward investors who follow demand trends, order books and margins together. Lupin, Dhoot Transmission and Talbros Automotive Components each have a clear plan to grow. Based on the 4 November 2026 close, Lupin trades at Rs 2,008.6, Dhoot Transmission at Rs 1,637.2 and Talbros Automotive Components at Rs 369.25. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma major, power conductor and gasket stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma major, power conductor and gasket stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma major, power conductor and gasket stocks?
Ans. Pharma major, power conductor and gasket stocks are listed companies that sell branded and generic medicines in India and overseas, make conductors, cables and wiring harnesses for power transmission, and produce gaskets, forgings and heat shields for vehicles. Their earnings depend on prescriptions, grid projects and vehicle output. This list looks at three of them, Lupin, Dhoot Transmission and Talbros Automotive Components, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which pharma major, power conductor and gasket stocks are covered in this list?
Ans. This list covers Lupin, Dhoot Transmission and Talbros Automotive Components. Based on the 4 November 2026 close, Lupin traded at Rs 2,008.6, Dhoot Transmission at Rs 1,637.2 and Talbros Automotive Components at Rs 369.25. Their return on equity ranges from 14.0% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.9% to 31.0%.
Why do pharma major, power conductor and gasket stocks have a strong future roadmap in India?
Ans. Pharma major, power conductor and gasket stocks have a strong roadmap in India because steady demand for quality medicines, large grid investment and rising vehicle output keep widening the market for these companies. The main drivers are as follows. Pharma. Branded and generic medicines reach more patients. Power conductors. Grid upgrades need new lines. Gaskets. Every engine needs sealing parts. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
How has Dhoot Transmission performed financially?
Ans. Revenue rose from Rs 1,551 crore in FY22 to Rs 4,564 crore in FY26, a compound annual growth rate of 31.0%. Net profit grew from Rs 164 crore in FY23 to Rs 397 crore in FY26, which works out to a compound annual growth rate of 34.3%. In the June 2026 quarter, revenue grew 49.9% year on year to Rs 1,460 crore, while net profit rose 37.8% to Rs 133 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 30,067 crore. The stock trades at a P/E of 75.8, above the industry P/E of 40.7. Looking ahead, the company is expanding capacity in power conductors and cables to serve utilities and grid projects, while its wiring harness business supplies vehicle makers. Rising spending on power transmission supports demand for its products.
How has Talbros Automotive Components performed financially?
Ans. Revenue rose from Rs 588 crore in FY22 to Rs 889 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 44.9 crore in FY22 to Rs 104 crore in FY26, which works out to a compound annual growth rate of 23.4%. In the June 2026 quarter, revenue grew 15.0% year on year to Rs 242 crore, while net profit rose 35.2% to Rs 30.0 crore. The company has a return on equity of 14.0%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 2,171 crore. The stock trades at a P/E of 19.4, below the industry P/E of 36.9. Looking ahead, its roadmap includes capacity in forgings, entry into products for electric vehicles and a growing export book. The aftermarket business offers steady demand through the vehicle’s life, which provides a base for earnings.
What risks should investors check before buying pharma major, power conductor and gasket stocks?
Ans. Investors should check a few risks before buying pharma major, power conductor and gasket stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma major, power conductor and gasket stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
